

## Publications authored by Heikki Artturi Seikkula

### Original articles:

1. Seikkula H, Syvänen KT, Kurki S, Mirtti T, Taimen P, Laato M, et al. Role of ultrasensitive prostates specific antigen in the follow-up of prostate cancer after radical prostatectomy. *Urol Oncol*. 2015;33(1):16.e1-.e7.
2. Saarinen I, Mirtti T, Seikkula H, Boström PJ, Taimen P. Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. *PLoS One*. 2015;10(10):e0140671.
3. Laajala TD#, Seikkula H#, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. *Sci Rep*. 2016;6:36161.
4. Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, et al. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. *Mod Pathol*. 2016;29(12):1565-74.
5. Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, et al. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. *Int J Cancer*. 2016;139(1):140-52
6. Seikkula HA, Kaipia AJ, Rantanen ME, Pitkaniemi JM, Malila NK, Bostrom PJ. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. *Acta Oncol*. 2017;56(7):971-7
7. Seikkula H, Janssen P, Tutolo M, Tosco L, Battaglia A, Moris L, et al. Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. *Front Oncol*. 2017;7:280
8. Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, et al. New prostate cancer grade grouping system predicts survival after radical prostatectomy. *Hum Pathol*. 2018;75:159-66.
9. Seikkula HA, Kaipia AJ, Ryyanen H, Seppä K, Pitkaniemi JM, Malila NK, et al. The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland. *Int J Cancer*. 2018;142(5):891-8
10. Seikkula H, Boström PJ, Seppä K, Pitkäniemi J, Malila N, Kaipia A. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation. *BMC Urol*. 2020;20(1):25
11. Seikkula H, Hirvonen E, Kaipia A, Boström PJ, Malila N, Pitkäniemi J. Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. *Cancer Epidemiol*. 2020;69:101807
12. Seikkula H, Kaipia A, Hirvonen E, Rantanen M, Pitkäniemi J, Malila N, et al. Vasectomy and the risk of prostate cancer in a Finnish nationwide population-based cohort. *Cancer Epidemiol*. 2020;64:101631
13. Erkkilä, K., T. Veitonmäki, O. Ettala, H. Ronkainen, T. Isotalo, T. Nykopp, H. Seikkula, M. Seppänen, M. Tramberger, C. Palmberg, A. Kilponen, P. H. Dimitri, S. Mustonen, and H. Nisen Does every Clavien-Dindo

complication matter? A national multi-center study in kidney cancer surgery. *Scand J Urol.* 2021;55(6):441-7

14. Nikulainen, I., A. P. Salminen, I. Jambor, H. Merisaari, V. Tammilehto, P. Taimen, H. Seikkula, and P. J. Boström. Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial). *Scand J Urol.* 2021;55(5):354-60
15. Cornford P, Smith EJ, MacLennan S, Pereira-Azevedo N, Roobol MJ, Lumen N, et al. MAGINE Collaborative (including Seikkula H) IMAGINE-IMPact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. *Eur Urol.* 2021;79(2):173-6
16. Uimonen M, Kuitunen I, Seikkula H, Mattila VM, Ponkilainen V. Healthcare lockdown resulted in a treatment backlog in elective urological surgery during COVID-19. *BJU Int.* 2021;128(1):33-5
17. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. PRONOUNCE study investigators (including H. Seikkula) Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. *Circulation.* 2021;144(16):1295-307
18. Ettala O, Jambor I, Montoya Perez I, Seppänen M, Kaipia A, Seikkula H, et al. Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0). *BMJ Open.* 2022;12(4):e053118
19. Haapiainen H, Kaipia A, Murtola T, Seikkula H, Seppänen M, Jämsä P, Raitanen MP. 3D laparoscopic prostatectomy: results of multicentre study. *Scand J Urol.* 2022;56(3):176-81
20. Nisen, H., K. Erkkilä, O. Ettala, H. Ronkainen, T. Isotalo, T. Nykopp, H. Seikkula, M. Seppänen, M. Tramberger, C. Palmberg, A. Kilponen, D. Pogodin-Hannolainen, S. Mustonen, and T. Veitonmäki, Intraoperative complications in kidney tumor surgery: critical grading for the European Association of Urology intraoperative adverse incident classification. *Scand J Urol.* 2022;56(4):293-300
21. Seikkula H, Kaipia A, Boström PJ, Malila N, Pitkäniemi J, Seppä K. Periodic trends in geographical variation of prostate cancer incidence and mortality in Finland between 1985 and 2019. *Acta Oncol.* 2022:1-7
22. Siltari, A., J. Riikonen, J. Koskimäki, T. Pakarainen, O. Ettala, P. Boström, H. Seikkula, A. Kotsar, T. Tammela, M. Helminen, P. V. Raitinen, T. Lehtimäki, M. Fode, P. Østergren, M. Borre, A. Rannikko, T. Marttila, A. Salonen, H. Ronkainen, S. Löffeler, and T. J. Murtola Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. *BMJ Open.* 2022;12(4):e050264
23. Yu, L., M. Toriseva, S. Afshan, M. Cangiano, V. Fey, A. Erickson, H. Seikkula, K. Alanen, P. Taimen, O. Ettala, M. Nurmi, P. J. Boström, M. Kallajoki, J. Tuomela, T. Mirtti, I. J. Beumer, M. Nees, and P. Härkönen. Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. *Cancers (Basel).* 2022;14(2)
24. MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, et al. \*IMAGINE Collaborative (including H.Seikkula). Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries. *Eur Urol.* 2023;83:393-401
25. Nikulainen, I., A. P. Salminen\*, H. Seikkula\*, M. Högerman, I. M. Perez, I. Koskinen, J. Sairanen, J. Nikkola, T. J. Murtola, M. H. Vaarala, S. Jousmäki, T. K. Nykopp, T. Isotalo, T. Marttila, A. Alibeto, M.

Seppänen, C. Palmberg, and P. J. Boström. Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland. *Acta Oncol.* 2023 Aug;62(8):829-835. \*Shared second authorship

26. Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; EMBARK Study. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. *N Engl J Med.* 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. PMID: 37851874.
27. Åkerla J, Helminen O, Väyrynen JP, Parkkinen A, Järvenpää H, Böhm J, Seikkula H. CD3+ and CD8+ T cell Based Immune Cell Score as a Prognostic Factor in Clear-Cell Renal Cell Carcinoma. *Acta Oncol* 2024;Mar 28;63:105-110
28. Jussila I, Ahtiainen JP, Laakkonen EK, Siltari A, Kaipia A, Jokela T, Kärkkäinen M, Newton R, Raastad T, Huhtala H, Murtola TJ, Seikkula H. Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol. *BJU Int.* 2024 Jul;134(1):110-118.
29. Seikkula H, Hyysalo J, Högerman M, Boström PJ, Ettala O. The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy. *BJUI Compass.* 2024 Sep 15;5(11):1106-1113. doi: 10.1002/bco2.413. Erratum in: *BJUI Compass.* 2024 Dec 30;5(12):1324-1329.
30. Nikulainen I, Salminen AP, Högerman M, Seikkula H, Boström PJ, The Finnish National Cystectomy Database Research Group. Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes. *Cancers (Basel).* 2025 Feb 3;17(3):505.
31. Jussila I, Ahtiainen JP, Laakkonen EK, Käkälä P, Parviainen M, Pohjolainen H, Aaltonen J, Onni N, Mikko K, Murtola TJ, Huhtala H, Seikkula H. Testosterone levels at diagnosis: A key predictor of overall survival among patients with prostate cancer. *BJUI Compass.* 2025 Feb 17;6(2):e484.

#### Reviews:

1. Seikkula H, Pettersson K, Boström PJ. PSA and blood test diagnostics of prostate cancer. *Duodecim.* 2015;131(17):1547-52.
2. Seikkula H, Mäkelä L, Visapää H, Anttinen M. Optimal Strategies for Managing Prostate-specific Antigen Recurrence After Primary Radiotherapy in Prostate Cancer: The Finnish Perspective. *Eur Urol Focus.* 2023 Sep;9(5):698-700.

#### Others:

1. Seikkula Heikki, Kaipia Antti, Sosioekonominen asema ja eturauhassyöpäkuolleisuus (lääketieteellinen pääkirjoitus) *Lääketieteellinen aikakauskirja Duodecim* 2018;134(19):1866–8
2. Murtola T, Seikkula H, Vehmanen L & Hervonen P Hervonen. Eturauhassyövän kastroatiohoidon haittavaikutukset. *Suomen lääkirilehti, Vuosikerta.* 76, Nro 45, Sivut 2647–2651
3. Murtola T, Siltari A, Jussila, Seikkula H, Minn H, Karihtala P, Sormunen J Liikunta syöpäpotilaiden kuntoutuksessa. *Duodecim* 2025; 141:301–8
4. Matikainen M, Kimmo T, Boström P, Kenttämies A, Paula L, Marttila T, et al. Eturauhassyöpä Käypä hoito-suosituksen tiivistelmä perusterveydenhuollolle. *Duodecim.* 2023;139(11):943-50.

## Conference publications:

1. Venhomaa T, Nikulainen I, Bläckberg M, Bro L, Brandt SB, Ettala O, et al. A prospective multinational and multi-institutional analysis of radical cystectomy for bladder cancer in the Nordic countries (NorCys-trial). *European Urology*. 2024;85(Suppl. 1):S302-S3.
2. Kaipia AJ, Seppä K, Hirvonen E, Malila N, Pitkäniemi J, Toppari J, et al. MP01-04 Geographical distribution of testicular cancer in Finland suggests in utero exposures as underlying causes behind the increased incidence. *Journal of Urology*. 2024;211(5S):e2.
3. Erickson A, Lahdensuo K, Saarinen I, Seikkula H, Bostrom PJ, Taimen P, Rannikko A, Mirtti T. PTEN status adds to CAPRA-S in predicting outcome after radical prostatectomy. In *CANCER RESEARCH 2018 Aug 1* (Vol. 78, No. 16, pp. 42-43). 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH.
4. L Yu, M Toriseva, A Erickson, H Seikkula, M Nurmi, P Taimen, P Boström, et al. Increased FGFR1 expression is associated with prostate cancer progression. *Cancer Research* 77 (13\_Supplement), 5730-573
5. L Yu, A Erickson, M Toriseva, T Elo, J Tuomela, H Seikkula, M Nurmi, et al. FGFR1 in prostate cancer progression. *Cancer Research* 76 (14\_Supplement), 4951-4951
6. K Erkkilä, T Veitonmaki, E Ettala, H Ronkainen, T Isotalo, T Nykopp, et al. Critical evaluation of the Clavien-Dindo classification for postoperative complications in renal tumor surgery, a national multi-center study from Finland. *EUROPEAN UROLOGY* 79, S792-S793
7. HV Haapiainen, T Murtola, H Seikkula, M Seppanen, P Jamsa, A Kaipia, et al. Multicenter study of Laparoscopic 3D prostatectomies in 3 central hospitals (Seinäjoki, Pori and Kokkola) in Finland. *SCANDINAVIAN JOURNAL OF UROLOGY* 53, 39-4
8. H Seikkula, P Boström, M Rantanen, J Pitkäniemi, N Malila, A Kaipia. Survival following primary androgen deprivation therapy or watchful waiting among older men with localized prostate cancer. *European Urology Supplements* 3 (16), e89-e90
9. Lan Yu, Miikka Tuomala, Mervi Toriseva, Teresa Elo, Johanna Tuomela, Heikki Seikkula, Martti Nurmi, Peter Boström, Tuomas Mirtti, Kalle Alanen, Markku Kallajoki, Pirkko Härkönen; Abstract 3454: High expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with a shortened time to biochemical recurrence after radical prostatectomy. *Cancer Res* 1 August 2015; 75 (15\_Supplement): 3454.
10. H Seikkula, S Kurki, K Syvänen, P Boström, M Laato. Mp74-07 use of ultrasensitive psa doubling time to estimate progression risk of prostate cancer after radical prostatectomy. *The Journal of Urology* 191 (4S), e858-e858

## Book chapters:

1. Kirurgia, 2024 (Duodecim); Chapters: 1. Virtsaumpi ja virtsarakon katetrointi, 2. Kivessyöpä

## Theses:

1. Doctoral Thesis: Studies on prostate-specific antigen and prostate cancer epidemiology. Faculty of Medicine, Surgery, Department of Urology, Doctoral Programme in Clinical Research (DPCR), University of Turku, 132, 2017. <http://urn.fi/URN:ISBN:978-951-29-7032-2>